Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP1A2 | P05177 | 2/20 | 0.69 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 9/20 | 0.67 |
| ▸ | LMNA | P02545 | 4/20 | 0.67 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.67 |
| ▸ | TSHR | P16473 | 1/20 | 0.67 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.62 |
| ▸ | POLB | P06746 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.52 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21500003 | 0.87 | CYP1A2 (0.53) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL3045605 | 0.77 | ALOX15 (1.00) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL21499825 | 0.69 | CYP1A2 (0.68) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL13310279 | 0.69 | SYK (0.54) | CYP1A2CYP2C19ALDH1A1LMNATSHR | |
| SCHEMBL24768999 | 0.68 | ALDH1A1 (0.44) | ALDH1A1LMNAL3MBTL1TSHRALOX15 | |
| SCHEMBL21499925 | 0.68 | ALDH1A1 (0.75) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL25857702 | 0.68 | KMT2A (0.39) | CYP1A2CYP2C19ALDH1A1LMNAL3MBTL1 | |
| SCHEMBL4316660 | 0.68 | KDM4E (0.51) | ALDH1A1LMNATSHRPOLBNPSR1 | |
| SCHEMBL23990001 | 0.67 | POLB (0.44) | ALDH1A1LMNAL3MBTL1POLBTDP1 | |
| SCHEMBL12053675 | 0.66 | GAA (0.44) | CYP1A2ALDH1A1LMNAL3MBTL1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-07-12 | — | — | US | claimed |
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2010-09-02 | — | — | US | claimed |
| US-20090131445-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-05-21 | — | — | US | claimed |
| EP-1799689-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-06-27 | — | — | EP | claimed |
| WO-2006044402-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | claimed |
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2012-07-12 | — | — | US | disclosed |
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2010-09-02 | — | — | US | disclosed |
| US-20090131445-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | COMPASS PHARMACEUTICALS LLC (US) | 2009-05-21 | — | — | US | disclosed |
| EP-1799689-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | Compass Pharmaceuticals LLC (US) | 2007-06-27 | — | — | EP | disclosed |
| WO-2006044402-A1 | FURAZANO `3, 4-B ! PYRAZYNES AND THEIR USE AS ANTI-TUMOR AGENTS | COMPASS PHARMACEUTICALS LLC (US) | 2006-04-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100222356-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | CDC73, VHL, RB1 | CYP1A2 1078/4885CYP2C19 1804/4885ALDH1A1 953/4885 |
| US-20090131445-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | CDC73, RB1, CA5A | CYP1A2 459/4885CYP2C19 909/4885ALDH1A1 449/4885 |
| US-20120178754-A1 | Furazano '3, 4-B! Pyrazines and Their Use as Anti-Tumor Agents | CDC73, VHL, RB1 | CYP1A2 1078/4885CYP2C19 1804/4885ALDH1A1 953/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.